graft-versus-host-disease
(3)
The Boston Biotech Betting That Cells Don't Have to Show Up to Heal You
Aegle Therapeutics skips the stem cell transplant and ships only the message the cell was trying to send - a cell-free vesicle therapy now in human trials for one of the cruelest skin diseases in medicine.
Orca Bio
Orca Bio is a late-stage biotechnology company in Menlo Park, California, building high-precision allogeneic cell therapies. Its proprietary single-cell sorting platform purifies donor immune and stem cells to engineer optimized therapeutic mixtures aimed at curing blood cancers and autoimmune diseases, with its lead candidate Orca-T currently under FDA priority review.
Nathaniel Fernhoff
Nathaniel Fernhoff is the CEO and Co-founder of Orca Bio, a late-stage biotechnology company headquartered in Menlo Park, California, developing high-precision allogeneic T-cell immunotherapies to treat blood cancers and autoimmune diseases. Holding a Ph.D. in Molecular and Cell Biology from UC Berkeley and dual Bachelor's degrees in Biological Sciences and Mathematics from Stanford, Fernhoff co-founded Orca Bio in 2016 based on decades-old Stanford research. He rose from Chief Scientific Officer to CEO in May 2025, leading the company through a landmark Phase 3 clinical trial for Orca-T - showing 78% survival free from chronic graft-versus-host disease versus 38% for standard-of-care - a BLA submission under FDA Priority Review, and a $250M Series F round bringing total funding to over $625M. With a 100,000-square-foot manufacturing facility in Sacramento capable of producing ~3,000 cell therapy products per year, Fernhoff is steering Orca Bio toward potential commercialization and a cure for blood diseases without compromise.